Boehringer Ingelheim Unit Looks to Sell Generics Business


Dec 05, 2013

Ben Venue Laboratories, the Bedford, Ohio-based subsidiary of German drugmaker Boehringer Ingelheim, has hired Bank of America Merrill Lynch to explore a possible sale of its generic sterile injectable drugs business.

Ben Venue had struggled to keep the Ohio site open after a series of drug quality problems and had been operating under a consent decree with FDA until ultimately deciding in October to cease production and avoid additional investment.

No potential sale price or bidders have been mentioned yet.

Read the Reuters release

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments